Basic Filitra Professional Information

• INN (International Nonproprietary Name): Vardenafil.
• Brand Names Available In Canada (English): Filitra Professional — 20mg sublingual tablet distributed by select online suppliers; Filitra Professionnel (French labelling stickers sometimes added by suppliers).
• ATC Code: G04BE09.
• Forms & Dosages: Sublingual tablet, 20mg, dissolved under the tongue; note in some sources there is mention of 100mg but the most widely accepted strength for Filitra Professional is 20mg.
• Manufacturers In Canada (English): Primary manufacturer listed in product information is Fortune Health Care Ltd (India); distribution in Canada is via select online suppliers rather than local manufacturing.
• Registration Status In Canada (English): Filitra Professional is not listed with Health Canada and has no Drug Identification Number (DIN); it is sold via cross‑border and international e‑pharmacies but is not locally authorised.
• OTC / Rx Classification: Prescription Only (Rx) as a drug class (vardenafil is prescription‑only globally). Filitra Professional is frequently sold online without prescription but it is not officially approved for over‑the‑counter retail use in regulated markets.

Latest Research Highlights

Patients often ask whether Filitra Professional works faster than standard tablets.

There are limited Canada‑specific randomized controlled trials on Filitra Professional between 2022 and 2025.

Most clinical evidence is extrapolated from the vardenafil class, including studies of Levitra® and Staxyn® formulations.

Pharmacokinetic work during 2022–2025 supports that sublingual or orally disintegrating formulations reach faster Tmax compared with conventional oral tablets.

Real‑world pharmacovigilance reports from online pharmacies note variable product quality for imported vardenafil products and case reports of adverse events when combined with nitrates or strong CYP3A4 inhibitors.

Data highlights from available sources show a reliably faster Tmax with sublingual dosing compared with oral tablets.

Common adverse events reported across vardenafil studies and post‑marketing reports include headache, flushing and visual changes.

• Evidence gaps: No Canada‑specific RCT data on Filitra Professional are available publicly.
• Evidence gaps: Exact onset time (minutes) for Filitra Professional compared with Levitra®/Staxyn® in Canadian populations is not specified.
• Evidence gaps: Standardized pharmacovigilance data for imported vardenafil products sold online are limited and variable.

Clinical Effectiveness In Canada

People want to know if Filitra Professional is as effective as other vardenafil products available in Canada.

Clinical effectiveness for vardenafil in erectile dysfunction is supported by class data showing improved erectile function scores compared with placebo.

Filitra Professional itself is not listed with Health Canada and does not have a Drug Identification Number (DIN).

In practice, Canadian clinicians prescribe Health Canada‑approved vardenafil products such as Levitra® or Staxyn® when available and appropriate.

Provincial formularies like Ontario Drug Benefit, BC PharmaCare and RAMQ typically list only DIN‑listed products and rarely reimburse imported brands without local authorisation.

DIN

Drug Identification Number issued by Health Canada to indicate a product is authorized for sale in Canada.

Health Canada Authorisation

Regulatory approval indicating safety, efficacy and quality review has been completed.

Unlicensed Import

A product supplied into Canada without a Canadian DIN or local authorisation and often sourced from international e‑pharmacies.

Patients seeking faster onset may ask pharmacists about sublingual vardenafil or vardenafil ODT alternatives.

Pharmacists should counsel patients about the regulatory status of imported products and advise reporting adverse events to Health Canada if suspected.

Indications And Expanded Uses

One common question is whether Filitra Professional can be used for conditions beyond erectile dysfunction.

Vardenafil is indicated for erectile dysfunction (ED) and this is the approved indication across vardenafil brands.

Unlike sildenafil or tadalafil, vardenafil is not approved for pulmonary arterial hypertension.

Off‑label uses of vardenafil are uncommon in Canadian practice.

Approved Indication

Erectile dysfunction (ED).

Off‑Label

Rare; clinician discretion required with documented informed consent when used outside approved indications.

• Clinical situations where vardenafil might be chosen: prior poor response to sildenafil, need for potentially faster onset, preference for sublingual route.
• Clinical situations where vardenafil might be avoided: severe cardiovascular disease or concurrent nitrate therapy.

Off‑label prescribing requires informed consent and clear documentation, and imported products without a DIN add medico‑legal complexity.

Standard recommended dose for Filitra Professional is 20 mg sublingual, taken about 30 minutes before activity.

Composition And Brand Landscape

Patients ask which companies make Filitra Professional and how it compares to other brands available in Canada.

INN: Vardenafil.

ATC Code: G04BE09.

Filitra Professional is marketed as a 20 mg sublingual tablet manufactured primarily by Fortune Health Care Ltd in India.

Packaging typically comes in blister packs of 4 or 10 tablets with English labelling; some Canadian suppliers add French stickers.

Health Canada‑approved vardenafil brands such as Levitra® and Staxyn® have DINs and established supply chains in Canada.

• Sublingual attribute: marketed for faster onset and avoidance of gastrointestinal absorption.
• Manufacturer: Fortune Health Care Ltd (India) is listed as the primary manufacturer in product information.
• Packaging origin: imported blister packs; English labels commonly used and French stickers occasionally added by suppliers.

Sublingual

Placed under the tongue to dissolve, allowing absorption across oral mucosa.

Orally Disintegrating Tablet (ODT)

Tablet that disintegrates on the tongue without the need for water; may have similar patient‑reported faster onset.

Be aware that foreign labelling without full bilingual information can cause confusion for francophone patients.

Contraindications And Special Precautions

Safety is a top concern, especially interactions with other heart medicines.

Absolute contraindications include concurrent nitrate use, severe cardiovascular disease, severe hepatic impairment (Child‑Pugh C), severe hypotension and hypersensitivity to vardenafil or excipients.

Relative contraindications requiring close monitoring include anatomical penile abnormalities, bleeding disorders, retinitis pigmentosa, moderate hepatic impairment and severe renal impairment.

• Absolute: concurrent nitrates — do not use.
• Absolute: known hypersensitivity to vardenafil.
• Absolute: severe cardiovascular instability (recent MI, unstable angina, severe arrhythmias).
• Relative: Peyronie’s disease or penile anatomical deformity — specialist input recommended.
• Relative: moderate liver disease or severe renal impairment — dose adjustments or avoidance may be necessary.

Emergency signs to watch for include priapism lasting more than four hours, chest pain or syncope.

If priapism occurs, seek emergency medical care immediately to reduce risk of permanent damage.

Pharmacists in community settings should document medication histories carefully to flag nitrate interactions and counsel older adults and patients in communities with higher cardiovascular disease prevalence.

Culturally safe communication and bilingual counselling are recommended when serving Indigenous and francophone patients.

Dosage Guidelines

Common questions include how much to take, when, and whether the dose should be adjusted for age or disease.

Standard regimen for Filitra Professional is one 20 mg sublingual tablet taken about 30 minutes before sexual activity.

Do not exceed one 20 mg tablet in any 24‑hour period.

Avoid use in children and adolescents; safety and efficacy are not established for those under 18.

Elderly patients (>65) should start at lower doses where possible due to increased risk of adverse effects.

• Administration tips: dissolve under the tongue and avoid heavy fatty meals that may delay onset.
• Avoid excessive alcohol before or after dosing because of increased dizziness and hypotension risk.
• Storage: keep below 30°C and protect from moisture; keep in original blister until use.

Onset Time

Time from dosing to beginning of effect; sublingual formulations aim for faster onset compared with oral tablets.

Tmax

The time to reach maximum plasma concentration; pharmacokinetic work indicates faster Tmax with sublingual dosing.

Sublingual Absorption

Absorption across oral mucosa that can reduce first‑pass GI metabolism and speed effect.

Interactions Overview

Most important safety advice: never mix vardenafil with nitrates.

Concurrent use of nitrates and vardenafil can cause life‑threatening hypotension.

Strong CYP3A4 inhibitors such as ritonavir and some azole antifungals can increase vardenafil exposure and risk adverse effects.

Alpha‑blockers have additive blood pressure lowering effects and require careful timing or dose adjustment.

Grapefruit juice inhibits CYP3A4 and can increase vardenafil exposure.

Heavy alcohol use may increase dizziness or hypotension when combined with vardenafil.

• High‑risk interactions: nitrates — do not combine under any circumstances.
• High‑risk interactions: strong CYP3A4 inhibitors — review co‑medication list and consider dose changes or alternatives.
• High‑risk interactions: alpha‑blockers — separate dosing and monitor blood pressure.

Canadian counselling should reflect common lifestyle factors such as alcohol use and recreational drugs that increase risks, including poppers which can cause dangerous interactions.

Document interactions in provincial e‑health records where available and report severe reactions to Health Canada.

Cultural Perceptions And Patient Habits

Privacy, evidence and bilingual information are frequent patient concerns.

Many Canadian men value discreet access, clear evidence of safety and efficacy, and competitive pricing.

Online forums and patient discussion boards often discuss imported ED medications, faster onset claims and worries about counterfeit products.

Rural patients report access barriers such as longer travel times to clinics and pharmacies, increased stigma and fewer sexual health services locally.

Telehealth has helped bridge some access gaps for remote and rural communities.

Indigenous communities may have historical mistrust of outside suppliers, and culturally safe approaches with community health workers improve uptake and safety.

• Common patient concerns: safety, regulatory approval, price and bilingual information.
• Preferred access channels: telemedicine consults, discreet home delivery and in‑person pharmacist counselling.

Pharmacists should proactively offer privacy, French translations and clear explanations about Filitra Professional lacking Health Canada authorisation.

Offer both in‑person and virtual counselling options to meet urban and rural preferences.

Availability And Pricing Patterns

Patients often compare price and convenience when deciding between approved brands and imported products.

Filitra Professional is distributed by select online suppliers in Canada but lacks a Health Canada listing and DIN.

Major Canadian pharmacy chains typically stock approved DIN products such as Levitra® or Staxyn® rather than imported Filitra Professional.

International e‑pharmacies and cross‑border sellers list Filitra Professional and often undercut Canadian retail pricing, but these options carry quality and regulatory risk.

Provincial drug plans such as Ontario Drug Benefit, BC PharmaCare and RAMQ generally reimburse DIN‑listed products only.

Shoppers should always check for a DIN, verify the pharmacy licence and obtain pharmacist counselling before purchasing imported products.

In our online pharmacy, filitra professional is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

• Questions to ask when shopping: Does the product have a DIN? Is the seller a licensed pharmacy? Is pharmacist counselling provided?
• Keep records and receipts for possible adverse event reporting to Health Canada.

Comparable Medicines And Preferences

Many patients ask whether to choose Filitra Professional, Levitra®, sildenafil or tadalafil.

Approved alternatives in Canada include vardenafil brands (Levitra®, Staxyn®), sildenafil (Viagra® and generics) and tadalafil (Cialis®).

Key differentiators are onset, duration, side‑effect profile and whether the product has a DIN for reimbursement.

• Vardenafil: reported faster onset when sublingual; commonly recommended when sildenafil response is poor.
• Sildenafil: widely available, generally reliable onset, shorter duration.
• Tadalafil: longest duration and available as a daily dosing option.

Canadian patients often prioritise DIN status and reimbursement, while some pay out‑of‑pocket for perceived faster onset from sublingual or ODT options.

Be cautious of counterfeit risk when buying non‑DIN imports.

FAQ Section

Is Filitra Professional approved in Canada?

No. Filitra Professional is not listed with Health Canada and has no DIN; vardenafil as a molecule is available in other branded products that are approved.

Can I legally buy Filitra Professional online from an international pharmacy?

You can purchase online, but imported drugs without a DIN carry regulatory, safety and quality risks and are unlikely to be reimbursed by provincial plans.

What are the main safety warnings I should know?

Do not combine vardenafil with nitrates; watch for severe hypotension; priapism lasting more than four hours is an emergency; coadministration with strong CYP3A4 inhibitors increases risk.

Will my provincial drug plan cover Filitra Professional?

Unlikely — Ontario Drug Benefit, BC PharmaCare and RAMQ generally cover DIN‑listed products only.

How do I report adverse events?

Report suspected adverse events to Health Canada via MedEffect and consult your pharmacist or physician immediately.

• Quick action steps: stop the drug if severe reaction suspected, seek medical care, keep packaging and receipts, report to Health Canada.

Guidelines For Proper Use

Both prescribers and pharmacists need a practical checklist to reduce risk and improve outcomes.

• Verify prescription legitimacy and check for a DIN; document if dispensing an imported product.
• Confirm absence of nitrates and review cardiovascular history before recommending vardenafil.
• Check for strong CYP3A4 inhibitors and alpha‑blocker co‑therapy.
• Counsel on a single 20 mg sublingual dose and maximum one tablet per 24 hours.
• Advise storage below 30°C, protect from moisture and keep in original blister until use.
• Educate about emergency signs such as priapism, chest pain and severe dizziness and instruct to seek immediate care.

DIN

Drug Identification Number indicating an authorised product in Canada.

Sublingual Administration

Tablet dissolves under the tongue for mucosal absorption.

Adverse Event Reporting

Report suspected adverse reactions to Health Canada via MedEffect and keep records of the product source.

Canadian pharmacies should insist on bilingual counselling (English/French), document informed consent when dispensing imported products and educate patients about lack of provincial reimbursement for unapproved imports.

Culturally competent counselling and telehealth follow‑up are recommended for Indigenous and rural populations.

When possible, recommend choosing a DIN‑approved alternative to reduce regulatory and quality risks.

Delivery Across Canada (English)